Biogen’s ‘Biomarkers’ Research to Find Ways to Tell Whether a Medication Has Been Successful

09 October 2018

At the 23rd International Annual Congress of the World Muscle Society, Biogen presented the findings of blood tests done on over 300 participants receiving nusinersen in their clinical trials.

They were looking at finding a way of telling whether a medication had been successful using a marker in the blood; these are called ‘biomarkers’. There was evidence that levels of phosphorylated neurofilament heavy chain (pNF-H) reduced immediately after treatment with nusinersen and stayed similar to levels of that seen in someone without SMA.